Benign Conditions

Latest News

Trial progresses of RECCE 327 for UTI and urosepsis
Trial progresses of RECCE 327 for UTI and urosepsis

March 14th 2024

The study is assessing RECCE 327 across the infusion times of 15, 20, 30, 45, and 60 minutes at the dose level of 3000 mg.

AUGS Clinical Consensus Statement on Postoperative Urinary Retention
AUGS Clinical Consensus Statement on Postoperative Urinary Retention

February 26th 2024

Woman talking with doctor | Image Credit: © bongkarn - stock.adobe.com
Trial to investigate efficacy of aloe vera in patients with interstitial cystitis

February 22nd 2024

Liposomal tacrolimus shows promise for hemorrhagic cystitis
Liposomal tacrolimus shows promise for hemorrhagic cystitis

September 21st 2023

blue tinted photo of a stethoscope lying on a laptop keyboard
ChatGPT has limitations in providing advice on urologic conditions

September 8th 2023

Video Interviews
Podcasts

More News

© 2024 MJH Life Sciences

All rights reserved.